{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "For BioPharma, Citing Relevant Art During Prosecution Does Not Appear to Minimize IPR Risk",
    "url": "https://www.lexblog.com/2015/08/31/for-biopharma-citing-relevant-art-during-prosecution-does-not-appear-to-minimize-ipr-risk/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-NETEFFTD",
        "url": "https://www.lexblog.com/lib/NETEFFTD/"
    },
    "datePublished": "2015-08-31T10:58:17-04:00",
    "dateModified": "2018-07-25T17:44:08-04:00",
    "author": {
        "@type": "Person",
        "name": "Robert Terzoli"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Seyfarth Shaw LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "BioLoquitur",
    "about": "Intellectual Property",
    "sourceUrl": "http://www.bioloquitur.com/?p=337",
    "sourceStability": "may-move"
}